Close

NewLink Genetics (NLNK) Announces Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML

December 3, 2018 5:57 AM EST Send to a Friend
NewLink Genetics Corporation (NASDAQ: NLNK) announced that updated Phase 1 data evaluating indoximod plus standard-of-care chemotherapy for the treatment of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login